BIO Announces Preliminary Program for the 2012 BIO Convention in China

Event to take place in Shanghai, China, October 24-25, 2012.</p>

Washington, D.C. (September 4, 2012) – The Biotechnology Industry Organization (BIO) announces panel sessions for the 2nd annual BIO Convention in China to be held October 24-25, 2012 in Shanghai, China. The event will highlight the latest issues and trends related to doing business in China, including globalizing Traditional Chinese Medicines, trends in cancer research and presenting new models of R&D structures.

“The program will feature biopharma executives from East and West sharing their insights and perspectives on issues critical for encouraging and supporting cross border deal-making," said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development. 

Three can’t miss panels include

  • Trends in Cancer Research and Oncology Treatment Development in China
Cancer is the leading cause of death in China, and novel oncology treatments are critical to preserving the nation’s public health. This panel will discuss trends in Chinese cancer research and survey the novel oncology drug R&D pipeline for China.
Wednesday, October 24th, 3:00 – 4:25 p.m.
Moderator:Richard Yeh, Head, China Healthcare Research, Citi Investment Research
Panelists: Yinxiang Wang, PhD, CEO & Chief Scientist, Zhejiang BetaPharma Co., Ltd. and Jinzi J. Wu, PhD, Co-Founder, President, & CEO, Ascletis Inc
  • Globalizing Traditional Chinese Medicines
China has used Traditional Chinese Medicine (TCM) for centuries and still comprises a substantial portion of the Chinese healthcare industry. With Western pharmas beginning to show an appetite for these treatments, many in-licensing and co-development opportunities exist. Biopharma executives from both China and the West will share their TCM strategies and current projects.
Thursday, October 25th, 2:00 – 3:25 p.m.
Moderator: Helen Chen, Director & Partner, L.E.K. Consulting
Panelists: Henry Sun, President & CEO, Tasly Pharmaceuticals, Inc. and Jian-ping Zuo, PhD, Professor and Director of Department of Pharmacology, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences
  • Development Trends (Part 1) - New Models of Cross-Border R&D Structures
With the recent flurry of drug development deals between multinational companies and Chinese biopharma companies, this panel will examine new models of R&D that are being pursued. Industry and academic researcher leaders will explore examples of successful cross-border drug development collaborations.
Thursday, October 25th, 12:30 – 1:55 p.m.
Moderator: Steve Yang, Vice President, Head of R&D, Asia and Emerging Markets, AstraZeneca, China
Panelists: Zafrira Avnur, PhD Head of Global Academic Innovation Partnering, Roche and Ralf Altmeyer, PhD, Director General, Institute Pasteur Shanghai 

Other BIO China sessions include:

  • Globalization of Chinese Companies
    This panel will explore the globalization of Chinese companies, starting with the nuances of conducting business with Western biopharma companies and how to go about selling products outside of China. Case studies showcasing strong, successful collaborations will provide strategic insight for Chinese companies eager to sell products beyond China’s borders.
  • Achieving Success via Innovation in Biosimilars
    Leading companies that have achieved global success in biosimilars, generic drug development and manufacturing will lend their insights on an intriguing panel discussion.
  • Comparative Legal Systems—U.S., Europe & China
    Attendees will learn how to navigate the complexities of the European and U.S. regulatory landscapes. Specifically, what are the barriers to entry in these markets and how can companies gain market access? Regulatory and legal experts will explore the similarities & differences between the U.S., Chinese & European regulatory systems.
  • Biopharma Strategy 101: Biopharma's China Business Plan
    Large biotech companies, particularly Westerners, have shown a great interest in China, but have a short history in the country and limited ground operations. A panel of biotech industry experts “trying to figure it out” will share their insights.
  • Adapting to China’s Changing Health Care System—Reimbursement, Health Care Reform & Affordability
    Affordability is a central focus of China’s healthcare reforms. Experts and representatives from the Chinese Government will tackle reimbursement, healthcare reform and private insurance issues.
  • Trends in Cancer Research and Oncology Treatment Development in China
    Cancer is the leading cause of death in China, and novel oncology treatments are critical to preserving the nation’s public health. This panel will discuss trends in Chinese cancer research and survey the novel oncology drug R&D pipeline for China.
  • Regulatory Review Process of New Medicines in China
    The rapid development of the Chinese pharmaceutical industry is presenting new opportunities for new medicine commercialization. Positive steps have been made towards drug registration standardization and the necessary levels of administrative investment. This panel will tackle how both Western and Chinese companies can take advantage of China’s review process to create mutually beneficial outcomes for patients and industry.
  • Leadership Models in Translating Innovative Sciences
    This panel will provide an overview of China’s translational medicine landscape and highlight U.S. and European programs that could serve as strong models for China.
  • Small Companies Thinking Big: China Operational Strategies
    Emerging and mid-sized biotech companies are exploring ways to enter China’s lucrative market and maximize their investment in the country. Industry experts and biotech executives will tackle the tough questions surrounding operational tactics in China.
  • Development Trends (Part 2) – New Models of R&D Structures in China

Backed by the government’s strong commitment to promoting innovation in the biotech sector, new R&D structures in China have emerged in recent years. Chinese biotech companies are also looking closer to home for their next partner to foster an innovative drug development pipeline. This panel will discuss how the country’s focus on biotech innovation has spurred new models of R&D structures for Chinese companies.  

In addition to panel sessions, BIO China will host keynote sessions, company presentations, partnering meetings and networking opportunities.

Dr. Michael Rosenblatt, M.D., executive vice president and chief medical officer for Merck, will provide one of two keynote addresses on October 25th. Directly following Dr. Rosenblatt’s keynote, Peng Wang, Ph.D., Chief Scientific Officer, Simcere will deliver his remarks. Governor Jon Huntsman, former U.S. Ambassador to China and Governor of Utah, will provide the third keynote address. Additional keynote speakers will be announced at a later date.

BIO brings to China more than 15 years of experience in organizing international conferences for the biotech industry, including the BIO International Convention – the global event for biotechnology.BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

For more information on the BIO Convention in China, please visit here.


Upcoming BIO Events 
September 12-13, 2012
Mumbai, India
September 19-21, 2012
Kansas City, MO
October 9-10, 2012
San Francisco, CA
October 10-12, 2012
Vancouver, Canada
October 24-25, 2012
Shanghai, China
November 12-14, 2012
Charleston, SC